The original version of this article unfortunately contained a mistake in the affiliation of Dr. Delmonte. The correct affiliation should be: Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. The original article has been corrected.
Gelsomino F., Tiseo M., Barbieri F., Riccardi F., Cavanna L., Frassoldati A., et al. (2021). Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3). BRITISH JOURNAL OF CANCER, 125(2), 306-306 [10.1038/s41416-021-01439-1].
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3)
Gelsomino F.Primo
;Frassoldati A.;Delmonte A.;Lamberti G.;Brocchi S.;Ardizzoni A.Ultimo
2021
Abstract
The original version of this article unfortunately contained a mistake in the affiliation of Dr. Delmonte. The correct affiliation should be: Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. The original article has been corrected.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
